Serum level of IL‐4 predicts response to topical immunotherapy with diphenylcyclopropenone in alopecia areata. Issue 3 (29th August 2018)

• Record Type: Journal Article
• Authors: Gong, Yugang; Zhao, Ying; Zhang, Xiaoting; Qi, Shiling; Li, Shuifeng; Ye, Yanting; Yang, Jian; Caulloo, Sillani; McElwee, Kevin J.; Zhang, Xingqi
• Other Names: McElwee Kevin J. guestEditor.; Tosti Antonella guestEditor.
• Is Part Of: Experimental dermatology. Volume 29:Issue 3(2020)
• Page Start: 231
• Page End: 238
• Publication Date: 2018-08-29
• Subjects: alopecia areata -- biomarkers -- diphenylcyclopropenone -- prognostic -- biomarkers -- therapeutic effect; Dermatology -- Periodicals; 616.5
• DOI: 10.1111/exd.13758
• Languages: English
• ISSNs: 0906-6705

Abstract

Abstract: Background: This study investigated predictors of response to topical diphenylyclopropenone (DPCP) immunotherapy in patients with alopecia areata (AA). Objective: To identify predictors of response, or resistance, to treatment for AA through clinical observations and serum tests. Methods: Eighty four AA patients were treated with DPCP. Serum cytokine levels were measured in 33 AA patients pre‐ and post‐treatment, and in 18 healthy controls, using ELISA assays. Results: Of patients, 56.1% responded to DPCP with satisfactory hair regrowth; the response rate was negatively correlated with hair loss extent. Before DPCP treatment, higher serum IFN‐γ and IL‐12 cytokine levels were observed in AA patients compared to healthy controls. Non‐responders to DPCP had significantly elevated serum IL‐4 pre‐treatment (3.07 fold higher) and lower IL‐12 levels compared with responders. After DPCP treatment, non‐responders had persistently high IL‐4, increased IL‐12, negligible decrease in IFN‐γ and decreased IL‐10. Post‐treatment DPCP responders exhibited significantly decreased IFN‐γ and IL‐12, and increased IL‐4 and IL‐10. Development of adverse side‐effects was significantly associated with higher pre‐treatment serum IgE levels. Limitations: A small number of subjects were evaluated. Conclusions: Potentially, elevated pre‐treatment serum levels of IL‐4 and IL‐12 can be used as unfavorable and favorable predictors of DPCP therapeutic effect, respectively. In addition, pre‐treatment elevated serum total IgE may predict increased risk for severe adverse side‐effects to DPCP application. Whether serum cytokine expression levels can be used as predictors of response to other forms of treatment is unknown, but it may warrant investigation in the development of personalized treatments for AA.